Israeli cancer immunotherapy firm Compugen said on Monday it had positive initial results from an ongoing early-stage study of its COM701 therapy in patients with advanced solid tumours who have exhausted all standard treatments.
Click here for original story, Compugen sees ‘encouraging signals’ from early-stage cancer trial
Source: Reuters Science News